Genentech fenebrutinib cuts relapsing MS relapses 51%-59%
04/21/2026 – 07:15 PM Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib…
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
F. Hoffmann-La Roche Ltd Basel, 13 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that…
Roche giredestrant NDA accepted by FDA for breast cancer
Roche (OTCQX: RHHBY) announced FDA acceptance of its New Drug Application for giredestrant…
Novartis reports final data of ALIGN trial in IgAN
Novartis has announced final data from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slowed kidney function…
Roche oral SERD giredestrant boosts iDFS in early breast cancer
Roche (OTCQX: RHHBY) reported positive Phase III results from the lidERA trial of…
Roche eyes Gazyva label expansion on positive Phase III kidney disease data
Roche is heading to regulators after its blockbuster kidney disease candidate, Gazyva (obinutuzumab), met its primary endpoint during…